KRX Bio Technology Transfer Index

Final data from the Phase 1b clinical trial of APB-A1 for thyroid eye disease (TED) is scheduled to be presented at the ENDO conference on June 13, 2026. High importance is estimated due to the typical >10% price impact of clinical data, scheduled.

The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.

Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.

Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.

Announced a strategic investment in US biotech 'General Proximity' to secure next-generation 'Induced Proximity' drug development technology, on April 30, 2026.

Announced Q1 2026 earnings with revenue of KRW 447.7 billion (+12.2% YoY) and operating profit of KRW 17.6 billion (+36.9% YoY), beating market expectations.

An executive vice president is scheduled to announce a long-term revenue target for Cenobamate (Xcopri), aiming for $1 billion in U.S. sales by 2029 at the Bio Korea 2026 event on April 29, 2026; high importance is estimated as the $1B target is a critical valuation milestone for blockbuster status, scheduled.

The company officially appointed Park Se-jin as the new CEO on April 29, 2026, following a pre-announcement on April 28, 2026; a 5-10% price impact is expected due to the leadership transition, expected.

Partner Compass Therapeutics announced on April 27 that the Phase 2/3 trial for biliary tract cancer drug Tovecimig (ABL001) met its Progression-Free Survival (PFS) endpoint but failed to meet the key Overall Survival (OS) endpoint. The news led to a stock price decline of over 20%.

Q1 2026 earnings release on 2026-04-28 with revenue of KRW 258.7 billion and operating profit of KRW 33.2 billion. The 30.8% profit growth driven by K-CAB royalties is estimated to have a 5-10% price impact, expected.

Kiwoom Securities analysts forecast that Q1 2026 profitability may be below expectations due to restructuring of domestic drug distribution channels and geopolitical risks affecting Nabota shipments to the Middle East, as of April 28, 2026, forecasted.

Announced the presentation of 9 anti-cancer new drug candidate studies at the American Association for Cancer Research (AACR) 2026, showcasing R&D capabilities in next-generation modalities like TPD, mRNA, and ADCs.

Voronoi announced positive interim results from the Phase 1a clinical trial of its NSCLC treatment 'VRN11' at the AACR 2026 conference, showing an objective response rate (ORR) of 85.7% and a favorable safety profile scheduled. High importance is estimated as clinical data of this magnitude typically results in a price impact exceeding 10%.